Loading data for DFTX — first visit, this takes a few seconds.

알림

Definium Therapeutics Inc... (DFTX)

NasdaqGS: DFTX · 실시간 가격 · USD

45.82

-0.36 (-0.78%)

종가 기준: Aug 20, 2026, 8:00 PM

44.75

-1.43%

애프터마켓: 6:04 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-0.78% (1D)

데이터 없음

매수호가	33.63
시가총액	6.1B
매출 (ttm)	n/a
순이익 (ttm)	-353.78M
	2.26
	-3.43
	n/a
	-24.21
P/B (ttm)	6.64
P/S (ttm)	n/a
실적 발표일	n/a

매도호가	57.7
거래량	1,746,550
평균 거래량 (20일)	3,028,916
시가	47.00
전일 종가	46.18
일중 범위	44.59 - 47.29
52주 범위	8.70 - 49.70
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

DFTX 소개

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum d...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 15, 2016

직원 수 105

상장 거래소 NasdaqGS

티커 DFTX

웹사이트 https://definiumtx.com

전체 기업 정보

재무 실적

2025년 Definium Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -183.79M로, 69.12% 증가했습니다.

재무제표

어닝 서프라이즈

Definium Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -1.44 예상치 하회 -0.89, 및 -188.00% 전년 대비 감소.

뉴스

5일 전 · Market Exclusive

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Curaleaf Holdings Announced Intention to Launch a Hostile Takeover Bid to Acquire Aurora Cannabis Organigram Posted Record Quarter as Sanity Group Acquisition Fueled Glo...

1주 전 · Simply Wall St.

Definium Therapeutics (DFTX) Voyage Data Puts Valuation Back In Focus

Definium Therapeutics (DFTX) is back in focus after reporting positive topline results from its Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. This event has quickly refocused atte...

1주 전 · Simply Wall St.

Is Successful Voyage Phase 3 Data Transforming the Investment Case For Definium Therapeutics (DFTX)?

In August 2026, Definium Therapeutics reported that its Phase 3 Voyage trial of DT120 ODT in generalized anxiety disorder met the primary HAM-A endpoint and all key secondary measures, delivering rapi...

1주 전 · Simply Wall St.

Definium Therapeutics (DFTX) Hits Phase 3 GAD Goals For DT120 ODT

Definium Therapeutics (NasdaqGS: DFTX) reported positive topline data from its pivotal Phase 3 Voyage trial of DT120 ODT in adults with generalized anxiety disorder. The study met all primary and key ...

1주 전 · MT Newswires

Definium Therapeutics' DT120 Data Boosts Confidence in Future Trials, RBC Capital Markets Says

Definium Therapeutics' (DFTX) phase 3 data for DT120 in generalized anxiety disorder looked better t

2 페이지 중 1

Definium Therapeutics Inc... (DFTX)